Abstract
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC).
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have